Parkinson’s disease symptoms that affect the quality of life of patients with the condition improved in studies of new drugs under investigation, according to new research coming from the annual meeting of the American Academy of Neurology. "With our most effective doses, we were able to show significant reductions in off-time in comparison with placebo, but importantly, we were able to do that without seeing a worsening of dyskinesia," said the lead author, Dr. C. Warren Olanow, the Henry P. and Georgette Goldschmidt professor of neurology and professor of neuroscience at the Icahn School of Medicine at Mount Sinai.
-Dr. C. Warren Olanow, Professor and Chair Emeritus, Neurology, Professor of Neuroscience, The Icahn School of Medicine at Mount Sinai